---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-23-007948"
form_type: "8-K"
ticker: null
cik: "0001828613"
company_name: "Stem Cell Inc."
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T06:12:00.096877+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Stem Cell Inc. acquires spinal cord injury therapy tech from related party for 2M shares; appoints Dr. Anand as CSO

## Summary
- Acquired stem cell-based Spinal Cord Injury Therapy Technology from Auto Stem Laboratories for 2M shares of common stock.
- Appointed Dr. Anand Kumar Arachimani as director and CSO effective Oct 1, 2023; he is also managing director of Auto Stem Labs (related party).
- Company changed name from Global Gold Royalty, Inc. to Stem Cell Inc. effective Oct 10, 2023, via shareholder vote.
- Board expects the acquisition to shift focus from precious metals to stem cell regenerative medicine biotechnology.

## SEC filing metadata
- accession: 0001477932-23-007948
- form_type: 8-K
- cik: 0001828613
- company_name: Stem Cell Inc.
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828613/000147793223007948/0001477932-23-007948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828613/000147793223007948/global_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-23-007948
- JSON: https://secwatch.observer/filing/0001477932-23-007948.json
- Plain text: https://secwatch.observer/filing/0001477932-23-007948.txt

## Key facts
- Executive change
  Dr. Anand Kumar Arachimani was appointed as director at Stem Cell Inc..
  - Action: appointed
  - Role: director
  source text: On October 1, 2023, the Board of Directors (the “Board”) of Stem Cell Inc. appointed Dr. Anand Kumar Arachimani as a director of the Board and Chief Scientific Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828613/000147793223007948/0001477932-23-007948-index.htm
- Executive change
  Dr. Anand Kumar Arachimani was appointed as Chief Scientific Officer at Stem Cell Inc..
  - Action: appointed
  - Role: Chief Scientific Officer
  source text: On October 1, 2023, the Board of Directors (the “Board”) of Stem Cell Inc. appointed Dr. Anand Kumar Arachimani as a director of the Board and Chief Scientific Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828613/000147793223007948/0001477932-23-007948-index.htm
- Governance Changes
  Stem Cell Inc.: Amended Articles of Incorporation to change company name to Stem Cell Inc (effective 2023-10-10).
  - Change: charter amendment
  - Effective: 2023-10-10
  source text: The Company has adopted an amendment to the Articles of Incorporation to effect a change of its name to Stem Cell Inc. and became effective from October 10, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828613/000147793223007948/0001477932-23-007948-index.htm
- Material Agreements
  Stem Cell Inc. entered into Intellectual Property Asset Transfer Agreement with Auto Stem Laboratories Private Limited (ASL) valued at two million shares of the Company’s common stock (effective 2023-10-18).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Auto Stem Laboratories Private Limited (ASL)
  - Value: two million shares of the Company’s common stock
  - Effective: 2023-10-18
  source text: On October 18, 2023 the Company entered into an Intellectual Property Asset Transfer Agreement with Auto Stem Laboratories Private Limited (ASL). In accordance with the terms of the Agreement, ASL will transfer its stem cell based Spinal Cord Injury Therapy Technology to the Company for a stock consideration of two million shares of the Company’s common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828613/000147793223007948/0001477932-23-007948-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.